Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway.
Wang L, Wang Y, Chen A, Teli M, Kondo R, Jalali A, Fan Y, Liu S, Zhao X, Siegel A, Minami K, Agarwal M, Li BY, Yokota H.
Wang L, et al. Among authors: teli m.
FASEB J. 2019 Dec;33(12):13710-13721. doi: 10.1096/fj.201901388R. Epub 2019 Oct 4.
FASEB J. 2019.
PMID: 31585508
Free PMC article.
Collectively, the results lay a foundation for further investigation of pitavastatin's therapeutic efficacy in tumor-induced bone loss, as well as VOC-based diagnosis of tumor progression and treatment efficacy.-Wang, L., Wang, Y., Chen, A., Teli, M., Kondo, R., Jal …
Collectively, the results lay a foundation for further investigation of pitavastatin's therapeutic efficacy in tumor-induced bone loss, as w …